文献速递神经免疫

多发性硬化升级治疗与早期强化治疗的临床结局比较

Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2019-01-01

该队列研究纳入592例多发性硬化患者,比较早期强化治疗(EIT)与一线中等疗效药物升级策略(ESC)的长期结局。结论支持早期强化治疗长期结局更优,但需前瞻性随机试验验证。

要点

  • 早期强化治疗组5年EDSS变化显著低于升级治疗组。
  • 早期强化治疗组持续残疾累积时间中位数长于升级组。
  • 60%升级至高效药物者在升级前已出现持续残疾累积。

核心结论

  • 真实世界中,早期强化治疗较一线中等疗效药物长期结局更有利。
  • 现行监测策略和升级方案可能反应不足。
  • 数据支持开展前瞻性随机临床试验。

研究设计与样本

  • 共720例处方疾病修饰治疗(DMT)患者,592例(82%)纳入分析。
  • 排除原因:首次在他处或私人治疗(n=39)、临床试验参与者(n=25)、临床数据不足(n=45)。
  • 按一线治疗策略分为早期强化治疗(EIT)组和中等疗效DMT升级(ESC)组。

主要发现

  • 592例患者症状发作时平均(SD)年龄为27.0(9.4)岁。
  • 校正相关协变量后,两组间SAD风险无差异;但60%升级至高效DMT者在升级前仍接受初始中等疗效治疗时已观察到SAD。

临床怎么用

  • 对于符合早期强化治疗选择标准的患者,可考虑早期使用高效DMT以改善长期残疾结局。
  • 对一线中等疗效治疗患者需加强监测,因现行升级方案可能反应不足。

局限性

  • 为观察性队列研究,存在选择偏倚可能,需前瞻性随机临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Uncertainty remains about how aggressively to treat early multiple sclerosis. High-efficacy disease-modifying therapies (DMTs) are often reserved for individuals expressing poor prognostic features at baseline. OBJECTIVE: To analyze long-term outcomes in a population-based cohort according to initial treatment strategy. DESIGN, SETTING AND PARTICIPANTS: In this cohort study, data were derived from January 1998 to December 2016, and analysis was performed in January 2017. From a total of 720 patients prescribed a DMT, 592 (82%) were included in analysis. Reasons for exclusion were first treated elsewhere or privately (n = 39), clinical trial participant (n = 25), and insufficient clinical data (n = 45). EXPOSURES: Patients were classified according to first-line treatment strategy: high-efficacy (early intensive treatment [EIT]) or moderate-efficacy DMT (escalation [ESC]). MAIN OUTCOMES AND MEASURES: Primary outcome was 5-year change in Expanded Disability Status Scale score. Secondary outcome was time to sustained accumulation of disability (SAD). Models were adjusted for sex, age at treatment, year of starting DMT, and escalation to high-efficacy treatment in the ESC group. RESULTS: Mean (SD) age of 592 patients at symptom onset was 27.0 (9.4) years. Mean (SD) 5-year change in Expanded Disability Status Scale score was lower in the EIT group than the ESC group (0.3 [1.5] vs 1.2 [1.5]); this remained significant after adjustment for relevant covariates (β = -0.85; 95% CI, -1.38 to -0.32; P = .002). Median (95% CI) time to SAD was 6.0 (3.17-9.16) years for EIT and 3.14 (2.77-4.00) years for ESC (P = .05). For those within the ESC group who escalated to high-efficacy DMT as second-line treatment, median (95% CI) time to SAD was 3.3 years (1.8-5.6; compared with EIT group log-rank test P = .08). After adjustment for relevant covariates, there was no difference in hazard of SAD between the groups. However, 60% of those who escalated to high-efficacy DMTs were observed to develop SAD while still receiving initial moderate-efficacy treatment before escalation. CONCLUSIONS AND RELEVANCE: In a real-life setting, long-term outcomes were more favorable following early intensive therapy vs first-line moderate-efficacy DMT. Contemporary surveillance strategies and escalation protocols may be insufficiently responsive. This finding is particularly relevant as patients in real-world practice are typically selected for an EIT approach to therapy on the basis of clinical and radiological features predictive of a poor outcome. These data support the need for a prospective randomized clinical trial.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Harding K, Williams O, Willis M, et al. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. JAMA Neurol. 2019. PMID: 30776055. doi:10.1001/jamaneurol.2018.4905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。